By Chris Wack
Akero Therapeutics shares doubled to $55.64 in premarket trading after the company said it saw positive preliminary topline results from its Phase 2b study evaluating the efficacy and safety of its lead product candidate, efruxifermin.
The company said that efruxifermin is for use in patients with biopsy-confirmed compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis.
Among patients with baseline and week 96 biopsies, 39% of patients treated with 50 milligrams experienced reversal of cirrhosis with no worsening of MASH, compared to 15% for placebo.
In a subgroup of patients with baseline and week 96 biopsies who were not taking GLP-1 at baseline, 45% in the 50 milligram efruxifermin group experienced reversal of cirrhosis with no worsening of MASH, compared to 17% for placebo, suggesting that the observed reversal of cirrhosis was not attributable to GLP-1 therapy.
Efruxifermin was reported to be generally well-tolerated. There were no deaths on efruxifermin, but one death in the placebo arm due to pneumonia. None of the serious adverse events were determined to be related to study drug.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 27, 2025 06:59 ET (11:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。